Cancer Center Support (CORE) Grant View Homepage


Ontology type: schema:MonetaryGrant     


Grant Info

YEARS

1978-2019

FUNDING AMOUNT

184657156 USD

ABSTRACT

DESCRIPTION (provided by applicant): The University of Texas MD Anderson Cancer Center is a free-standing comprehensive cancer center within the University of Texas system. In 2011, the institution marked its 70th anniversary and it welcomed Ronald DePinho, M.D., as its fourth full-time president and PI of the CCSG. The mission of MD Anderson is to eliminate cancer in Texas, the nation and the world through outstanding integrated programs of patient care, research, education and prevention. MD Anderson is dedicated wholly to the study of cancer involving a continuum of basic, clinical and population-based investigation, with an emphasis on multidisciplinary translational research. During the last 5 years, the number of cancer center members has increased 14%, facilities including those under construction have increased 56% and new patients have increased to 34,000 annually. Annual citations in Web of Science have increased to 2507 in 2011 (16.5%), including 283 articles in journals with an impact factor >10, reflecting substantial contributions to cancer research. The total research budget increased 40% from $445 million to $624 million. NCI grant support has increased from $115M to $120M (3%) with the largest number of NCI grants for any center (>220), including 11 SPOREs and 13 P01s. Research Programs remain at 19 and support is requested for 16 shared resources. Since the last CCSG renewal, basic science has been strengthened substantially with recruitment of world class leaders in immunology, genomics, proteomics, drug discovery and cancer biology. Translational research has been enhanced and strategic planning implemented to accelerate reductions in cancer deaths in this decade, through MD Anderson's 'moon shot' efforts across the cancer care continuum focused on several major cancers. These planning efforts were made possible by the CCSG disease programs and their well-established multi-disciplinary interactions. Since the last renewal 21 new agents developed at MD Anderson have entered clinical trials, 8 additional agents are expected to enter clinical trials in the next year and 12 INDs were prepared by the cancer center. Clinical research has been strengthened with new leadership, further development of infrastructure and data bases, and emphasis on hypothesis driven, investigator initiated trials. Cancer is a global problem, and MD Anderson has built a network of 26 Sister Institutions in 19 countries to facilitate research and educational activities. Cancer prevention and survivorship is a priority for MD Anderson with an emphasis on molecular epidemiology, behavioral science, clinical cancer prevention and early detection research to reduce the burden of cancer within Texas and worldwide. More... »

URL

http://projectreporter.nih.gov/project_info_description.cfm?aid=9757183

Related SciGraph Publications

  • 2019-12. Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer in NATURE COMMUNICATIONS
  • 2019-12. Stem cell proliferation is induced by apoptotic bodies from dying cells during epithelial tissue maintenance in NATURE COMMUNICATIONS
  • 2019-12. Global phosphoproteomic analysis reveals ARMC10 as an AMPK substrate that regulates mitochondrial dynamics in NATURE COMMUNICATIONS
  • 2019-12. The Late Positive Potentials Evoked by Cigarette-Related and Emotional Images Show no Gender Differences in Smokers in SCIENTIFIC REPORTS
  • 2019-12. A novel ex vivo tumor system identifies Src-mediated invasion and metastasis in mesenchymal tumor cells in non-small cell lung cancer in SCIENTIFIC REPORTS
  • 2019-12. O-GlcNAc Transferase Inhibition Differentially Affects Breast Cancer Subtypes. in SCIENTIFIC REPORTS
  • 2019-12. Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity in NATURE COMMUNICATIONS
  • 2019-12. The combined effect of physical activity and sedentary behavior on subclinical atherosclerosis: a cross-sectional study among Mexican Americans in BMC PUBLIC HEALTH
  • 2019-12. Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2019-12. Deregulated Gab2 phosphorylation mediates aberrant AKT and STAT3 signaling upon PIK3R1 loss in ovarian cancer in NATURE COMMUNICATIONS
  • 2019-12. Comparison between dopaminergic and non-dopaminergic neurons in the VTA following chronic nicotine exposure during pregnancy in SCIENTIFIC REPORTS
  • 2019-12. A prophylactic α-Gal-based glycovaccine effectively protects against murine acute Chagas disease in NPJ VACCINES
  • 2019-12. Breast cancer quantitative proteome and proteogenomic landscape. in NATURE COMMUNICATIONS
  • 2019-12. Enteral Activation of WR-2721 Mediates Radioprotection and Improved Survival from Lethal Fractionated Radiation in SCIENTIFIC REPORTS
  • 2019-12. Streamlined computational pipeline for genetic background characterization of genetically engineered mice based on next generation sequencing data in BMC GENOMICS
  • 2019-12. Cell type-specific function of TRAF2 and TRAF3 in regulating type I IFN induction in CELL & BIOSCIENCE
  • 2019-12. FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation in NATURE COMMUNICATIONS
  • 2019-12. A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin Lymphoma in SCIENTIFIC REPORTS
  • 2019-12. G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma in NATURE COMMUNICATIONS
  • 2019-12. ElemCor: accurate data analysis and enrichment calculation for high-resolution LC-MS stable isotope labeling experiments in BMC BIOINFORMATICS
  • 2019-12. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2019-04-11. Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1). in BREAST CANCER RESEARCH AND TREATMENT
  • 2019-04. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study in INVESTIGATIONAL NEW DRUGS
  • 2019-04. Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition in ONCOGENE
  • 2019-04. Do Internal Mammary Nodes Matter? in ANNALS OF SURGICAL ONCOLOGY
  • 2019-04-01. Educating Surgical Oncology Providers on Perioperative Opioid Use: Results of a Departmental Survey on Perceptions of Opioid Needs and Prescribing Habits in ANNALS OF SURGICAL ONCOLOGY
  • 2019-04. Comparative Analysis of Intra-arterial Cone-Beam Versus Conventional Computed Tomography During Hepatic Arteriography for Transarterial Chemoembolization Planning in CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY
  • 2019-04. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer in NATURE MEDICINE
  • 2019-03-25. The SERM Saga, Something from Nothing: American Cancer Society/SSO Basic Science Lecture in ANNALS OF SURGICAL ONCOLOGY
  • 2019-03-06. An Efficient Nonparametric Estimate for Spatially Correlated Functional Data in STATISTICS IN BIOSCIENCES
  • 2019-03-04. Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors in INTERNATIONAL JOURNAL OF HEMATOLOGY
  • 2019-03. Identification of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8+ lymphocytes in MODERN PATHOLOGY
  • 2019-03. Concept domain validation and item generation for the Treatment-Induced Neuropathy Assessment Scale (TNAS) in SUPPORTIVE CARE IN CANCER
  • 2019-03. Economic Burden of Renal Cell Carcinoma—Part I: An Updated Review in PHARMACOECONOMICS
  • 2019-03. Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux in ONCOGENE
  • 2019-03. Pathways to Vitality: the Role of Mindfulness and Coping in MINDFULNESS
  • 2019-03. Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma in ONCOGENE
  • 2019-03. Dynamic reorganization of the genome shapes the recombination landscape in meiotic prophase in NATURE STRUCTURAL & MOLECULAR BIOLOGY
  • 2019-02-28. Significance of Cancer Cells at the Vein Edge in Patients with Pancreatic Adenocarcinoma Following Pancreatectomy with Vein Resection in JOURNAL OF GASTROINTESTINAL SURGERY
  • 2019-02-26. Lipocalin-2 is dispensable in inflammation-induced sickness and depression-like behavior in PSYCHOPHARMACOLOGY
  • 2019-02. Lymphatic endothelial cells regulate B-cell homing to lymph nodes via a NIK-dependent mechanism in CELLULAR & MOLECULAR IMMUNOLOGY
  • 2019-02. Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells in BLOOD CANCER JOURNAL
  • 2019-02. Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules in INVESTIGATIONAL NEW DRUGS
  • 2019-02. Diet quality and Gleason grade progression among localised prostate cancer patients on active surveillance in BRITISH JOURNAL OF CANCER
  • 2019-02. Androgen Receptor Signaling in Castration-Resistant Prostate Cancer Alters Hyperpolarized Pyruvate to Lactate Conversion and Lactate Levels In Vivo in MOLECULAR IMAGING AND BIOLOGY
  • 2019-01-31. Nudt21 regulates the alternative polyadenylation of Pak1 and is predictive in the prognosis of glioblastoma patients in ONCOGENE
  • 2019-01-19. Assessment of baseline symptom burden in treatment-naïve patients with lung cancer: an observational study in SUPPORTIVE CARE IN CANCER
  • 2019-01. Comparative efficacy of adjuvant trastuzumab-containing chemotherapies for patients with early HER2-positive primary breast cancer: a network meta-analysis in BREAST CANCER RESEARCH AND TREATMENT
  • 2019-01. Surgical Resection for Recurrence After Two-Stage Hepatectomy for Colorectal Liver Metastases Is Feasible, Is Safe, and Improves Survival in JOURNAL OF GASTROINTESTINAL SURGERY
  • 2019-01. Model diagnostics for the proportional hazards model with length-biased data in LIFETIME DATA ANALYSIS
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2211", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }
        ], 
        "amount": {
          "currency": "USD", 
          "type": "MonetaryAmount", 
          "value": "184657156"
        }, 
        "description": "DESCRIPTION (provided by applicant): The University of Texas MD Anderson Cancer Center is a free-standing comprehensive cancer center within the University of Texas system. In 2011, the institution marked its 70th anniversary and it welcomed Ronald DePinho, M.D., as its fourth full-time president and PI of the CCSG. The mission of MD Anderson is to eliminate cancer in Texas, the nation and the world through outstanding integrated programs of patient care, research, education and prevention. MD Anderson is dedicated wholly to the study of cancer involving a continuum of basic, clinical and population-based investigation, with an emphasis on multidisciplinary translational research. During the last 5 years, the number of cancer center members has increased 14%, facilities including those under construction have increased 56% and new patients have increased to 34,000 annually. Annual citations in Web of Science have increased to 2507 in 2011 (16.5%), including 283 articles in journals with an impact factor >10, reflecting substantial contributions to cancer research. The total research budget increased 40% from $445 million to $624 million. NCI grant support has increased from $115M to $120M (3%) with the largest number of NCI grants for any center (>220), including 11 SPOREs and 13 P01s. Research Programs remain at 19 and support is requested for 16 shared resources. Since the last CCSG renewal, basic science has been strengthened substantially with recruitment of world class leaders in immunology, genomics, proteomics, drug discovery and cancer biology. Translational research has been enhanced and strategic planning implemented to accelerate reductions in cancer deaths in this decade, through MD Anderson's 'moon shot' efforts across the cancer care continuum focused on several major cancers. These planning efforts were made possible by the CCSG disease programs and their well-established multi-disciplinary interactions. Since the last renewal 21 new agents developed at MD Anderson have entered clinical trials, 8 additional agents are expected to enter clinical trials in the next year and 12 INDs were prepared by the cancer center. Clinical research has been strengthened with new leadership, further development of infrastructure and data bases, and emphasis on hypothesis driven, investigator initiated trials. Cancer is a global problem, and MD Anderson has built a network of 26 Sister Institutions in 19 countries to facilitate research and educational activities. Cancer prevention and survivorship is a priority for MD Anderson with an emphasis on molecular epidemiology, behavioral science, clinical cancer prevention and early detection research to reduce the burden of cancer within Texas and worldwide.", 
        "endDate": "2019-06-30T00:00:00Z", 
        "funder": {
          "id": "https://www.grid.ac/institutes/grid.48336.3a", 
          "type": "Organization"
        }, 
        "id": "sg:grant.2438826", 
        "identifier": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "2438826"
            ]
          }, 
          {
            "name": "nih_id", 
            "type": "PropertyValue", 
            "value": [
              "P30CA016672"
            ]
          }
        ], 
        "inLanguage": [
          "en"
        ], 
        "keywords": [
          "education", 
          "emphasis", 
          "Texas System", 
          "additional agents", 
          "Ronald DePinho", 
          "clinical research", 
          "global problem", 
          "network", 
          "investigators", 
          "several major cancers", 
          "molecular epidemiology", 
          "translational research", 
          "population", 
          "P01", 
          "description", 
          "survivorship", 
          "applicants", 
          "article", 
          "Texas", 
          "impact factor >10", 
          "cancer biology", 
          "decades", 
          "immunology", 
          "drug discovery", 
          "web", 
          "hypothesis", 
          "cancer research", 
          "spores", 
          "educational activities", 
          "world", 
          "nation", 
          "planning efforts", 
          "CCSG", 
          "cancer care continuum", 
          "further development", 
          "burden", 
          "genomics", 
          "NCI grant support", 
          "facilities", 
          "substantial contribution", 
          "early detection research", 
          "multidisciplinary translational research", 
          "basic science", 
          "institutions", 
          "University", 
          "years", 
          "M.D.", 
          "research", 
          "total research budget", 
          "new leadership", 
          "Texas MD Anderson Cancer Center", 
          "journals", 
          "Research Programs", 
          "cancer prevention", 
          "cancer", 
          "recruitment", 
          "next year", 
          "Cancer Center Support", 
          "large number", 
          "Moon", 
          "cancer center members", 
          "countries", 
          "core", 
          "support", 
          "continuum", 
          "last renewal 21 new agents", 
          "ind", 
          "efforts", 
          "data base", 
          "grant", 
          "proteomics", 
          "mission", 
          "program", 
          "world class leaders", 
          "behavioral sciences", 
          "reduction", 
          "prevention", 
          "infrastructure", 
          "patient care", 
          "investigation", 
          "construction", 
          "clinical trials", 
          "last CCSG renewal", 
          "cancer center", 
          "annual citations", 
          "MD Anderson", 
          "clinical cancer prevention", 
          "center", 
          "strategic planning", 
          "free-standing comprehensive cancer center", 
          "trials", 
          "fourth full-time president", 
          "Pi", 
          "number", 
          "NCI Grant", 
          "multi-disciplinary interaction", 
          "Sister Institutions", 
          "priority", 
          "science", 
          "shared resources", 
          "CCSG disease programs", 
          "70th anniversary", 
          "study", 
          "cancer death", 
          "new patients"
        ], 
        "name": "Cancer Center Support (CORE) Grant", 
        "recipient": [
          {
            "id": "https://www.grid.ac/institutes/grid.240145.6", 
            "type": "Organization"
          }, 
          {
            "affiliation": {
              "id": "https://www.grid.ac/institutes/grid.240145.6", 
              "name": "UNIVERSITY OF TX MD ANDERSON CAN CTR", 
              "type": "Organization"
            }, 
            "familyName": "PISTERS", 
            "givenName": "PETER W", 
            "id": "sg:person.01075456557.33", 
            "type": "Person"
          }, 
          {
            "member": "sg:person.01075456557.33", 
            "roleName": "PI", 
            "type": "Role"
          }
        ], 
        "sameAs": [
          "https://app.dimensions.ai/details/grant/grant.2438826"
        ], 
        "sdDataset": "grants", 
        "sdDatePublished": "2019-03-07T12:11", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com.uberresearch.data.processor/core_data/20181219_192338/projects/base/nih_projects_4.xml.gz", 
        "startDate": "1978-07-01T00:00:00Z", 
        "type": "MonetaryGrant", 
        "url": "http://projectreporter.nih.gov/project_info_description.cfm?aid=9757183"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/grant.2438826'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/grant.2438826'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/grant.2438826'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/grant.2438826'


     

    This table displays all metadata directly associated to this object as RDF triples.

    149 TRIPLES      19 PREDICATES      127 URIs      119 LITERALS      5 BLANK NODES

    Subject Predicate Object
    1 sg:grant.2438826 schema:about anzsrc-for:2211
    2 schema:amount Nc131e4052ff34903896e68e564983c43
    3 schema:description DESCRIPTION (provided by applicant): The University of Texas MD Anderson Cancer Center is a free-standing comprehensive cancer center within the University of Texas system. In 2011, the institution marked its 70th anniversary and it welcomed Ronald DePinho, M.D., as its fourth full-time president and PI of the CCSG. The mission of MD Anderson is to eliminate cancer in Texas, the nation and the world through outstanding integrated programs of patient care, research, education and prevention. MD Anderson is dedicated wholly to the study of cancer involving a continuum of basic, clinical and population-based investigation, with an emphasis on multidisciplinary translational research. During the last 5 years, the number of cancer center members has increased 14%, facilities including those under construction have increased 56% and new patients have increased to 34,000 annually. Annual citations in Web of Science have increased to 2507 in 2011 (16.5%), including 283 articles in journals with an impact factor >10, reflecting substantial contributions to cancer research. The total research budget increased 40% from $445 million to $624 million. NCI grant support has increased from $115M to $120M (3%) with the largest number of NCI grants for any center (>220), including 11 SPOREs and 13 P01s. Research Programs remain at 19 and support is requested for 16 shared resources. Since the last CCSG renewal, basic science has been strengthened substantially with recruitment of world class leaders in immunology, genomics, proteomics, drug discovery and cancer biology. Translational research has been enhanced and strategic planning implemented to accelerate reductions in cancer deaths in this decade, through MD Anderson's 'moon shot' efforts across the cancer care continuum focused on several major cancers. These planning efforts were made possible by the CCSG disease programs and their well-established multi-disciplinary interactions. Since the last renewal 21 new agents developed at MD Anderson have entered clinical trials, 8 additional agents are expected to enter clinical trials in the next year and 12 INDs were prepared by the cancer center. Clinical research has been strengthened with new leadership, further development of infrastructure and data bases, and emphasis on hypothesis driven, investigator initiated trials. Cancer is a global problem, and MD Anderson has built a network of 26 Sister Institutions in 19 countries to facilitate research and educational activities. Cancer prevention and survivorship is a priority for MD Anderson with an emphasis on molecular epidemiology, behavioral science, clinical cancer prevention and early detection research to reduce the burden of cancer within Texas and worldwide.
    4 schema:endDate 2019-06-30T00:00:00Z
    5 schema:funder https://www.grid.ac/institutes/grid.48336.3a
    6 schema:identifier N13766a00449344f09dd1a45cdf3371c5
    7 N1b980bcf7110436fb93310f1b43f6598
    8 schema:inLanguage en
    9 schema:keywords 70th anniversary
    10 CCSG
    11 CCSG disease programs
    12 Cancer Center Support
    13 M.D.
    14 MD Anderson
    15 Moon
    16 NCI Grant
    17 NCI grant support
    18 P01
    19 Pi
    20 Research Programs
    21 Ronald DePinho
    22 Sister Institutions
    23 Texas
    24 Texas MD Anderson Cancer Center
    25 Texas System
    26 University
    27 additional agents
    28 annual citations
    29 applicants
    30 article
    31 basic science
    32 behavioral sciences
    33 burden
    34 cancer
    35 cancer biology
    36 cancer care continuum
    37 cancer center
    38 cancer center members
    39 cancer death
    40 cancer prevention
    41 cancer research
    42 center
    43 clinical cancer prevention
    44 clinical research
    45 clinical trials
    46 construction
    47 continuum
    48 core
    49 countries
    50 data base
    51 decades
    52 description
    53 drug discovery
    54 early detection research
    55 education
    56 educational activities
    57 efforts
    58 emphasis
    59 facilities
    60 fourth full-time president
    61 free-standing comprehensive cancer center
    62 further development
    63 genomics
    64 global problem
    65 grant
    66 hypothesis
    67 immunology
    68 impact factor >10
    69 ind
    70 infrastructure
    71 institutions
    72 investigation
    73 investigators
    74 journals
    75 large number
    76 last CCSG renewal
    77 last renewal 21 new agents
    78 mission
    79 molecular epidemiology
    80 multi-disciplinary interaction
    81 multidisciplinary translational research
    82 nation
    83 network
    84 new leadership
    85 new patients
    86 next year
    87 number
    88 patient care
    89 planning efforts
    90 population
    91 prevention
    92 priority
    93 program
    94 proteomics
    95 recruitment
    96 reduction
    97 research
    98 science
    99 several major cancers
    100 shared resources
    101 spores
    102 strategic planning
    103 study
    104 substantial contribution
    105 support
    106 survivorship
    107 total research budget
    108 translational research
    109 trials
    110 web
    111 world
    112 world class leaders
    113 years
    114 schema:name Cancer Center Support (CORE) Grant
    115 schema:recipient N64c687ed80ba49a3a9f99900bb7aa079
    116 sg:person.01075456557.33
    117 https://www.grid.ac/institutes/grid.240145.6
    118 schema:sameAs https://app.dimensions.ai/details/grant/grant.2438826
    119 schema:sdDatePublished 2019-03-07T12:11
    120 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    121 schema:sdPublisher Nc1f4a91431264ed6892735f474818479
    122 schema:startDate 1978-07-01T00:00:00Z
    123 schema:url http://projectreporter.nih.gov/project_info_description.cfm?aid=9757183
    124 sgo:license sg:explorer/license/
    125 sgo:sdDataset grants
    126 rdf:type schema:MonetaryGrant
    127 N13766a00449344f09dd1a45cdf3371c5 schema:name nih_id
    128 schema:value P30CA016672
    129 rdf:type schema:PropertyValue
    130 N1b980bcf7110436fb93310f1b43f6598 schema:name dimensions_id
    131 schema:value 2438826
    132 rdf:type schema:PropertyValue
    133 N64c687ed80ba49a3a9f99900bb7aa079 schema:member sg:person.01075456557.33
    134 schema:roleName PI
    135 rdf:type schema:Role
    136 Nc131e4052ff34903896e68e564983c43 schema:currency USD
    137 schema:value 184657156
    138 rdf:type schema:MonetaryAmount
    139 Nc1f4a91431264ed6892735f474818479 schema:name Springer Nature - SN SciGraph project
    140 rdf:type schema:Organization
    141 anzsrc-for:2211 schema:inDefinedTermSet anzsrc-for:
    142 rdf:type schema:DefinedTerm
    143 sg:person.01075456557.33 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
    144 schema:familyName PISTERS
    145 schema:givenName PETER W
    146 rdf:type schema:Person
    147 https://www.grid.ac/institutes/grid.240145.6 schema:name UNIVERSITY OF TX MD ANDERSON CAN CTR
    148 rdf:type schema:Organization
    149 https://www.grid.ac/institutes/grid.48336.3a schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...